CDXS News and Press, Codexis Inc. From 08/02/21

REDWOOD CITY, Calif. and KALAMAZOO, Mich., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, and Kalsec, Inc., a leading global producer of natural spice and herb extracts, colors, food protection ...

Codexis (CDXS) and Kalsec have expanded their research collaboration and entered into an exclusive supply agreement for a novel enzyme to produce Kalsec’s newest natural hop acid.The enzyme is expected to enable commercial-scale production of Kalsec’s newest natural hop acid by ...

REDWOOD CITY, Calif. and KALAMAZOO, Mich., July 26, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, and Kalsec, Inc., a leading global producer of natural spice and herb extracts, colors, food protection ...

REDWOOD CITY, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report its financial results for the second quarter of 2021 on Thursday, August 5, 2021, followin...

Are These The Best Synthetic Biology Stocks To Buy Right Now? As we begin another week of trading, investors would be looking for good stocks to invest in. If anything, emerging sectors of the stock market such as synthetic biology (SB) stocks could be worth considering now. Bef...

REDWOOD CITY, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the completion of the CodeEvolver ® platform technology transfer with Novartis Pharma AG (“Novartis...

REDWOOD CITY, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced it earned a significant milestone payment related to the licensing of its proprietary CodeEvolver® protein eng...

Fokusiert/iStock via Getty Images A receipt of a new purchase order worth up to $13.9M from an unnamed customer for a proprietary high-performance enzyme product prompted Codexis ([[CDXS]] +12.7%) to raise its 2021 guidance. Noting the value of the order as Codexis management initially i...

REDWOOD CITY, Calif., June 17, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, is raising its guidance for 2021, following the receipt of a binding purchase order for up to $13.9 million of a proprietary ...

Codexis (CDXS) has expanded its strategic collaboration and license agreement with Takeda Pharmaceutical (TAK) for the research and development of an additional gene therapy for a lysosomal storage disorder.This brings the total number of programs under the agreement to four. Under the terms ...